Enterprise Value
-30.42M
Cash
87.12M
Avg Qtr Burn
-17.48M
Short % of Float
9.88%
Insider Ownership
0.70%
Institutional Own.
87.91%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LYR-210 (anti-inflammatory implantable drug matrix) Details Rhinosinusitis, Chronic rhinosinusitis, Neurological disorder | Phase 3 Update | |
LYR-220 (Long-acting Mometasone Furoate) Details Chronic rhinosinusitis | Phase 2 Update |